Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in...
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
About this item
Full title
Author / Creator
Publisher
Tokyo: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Cancer cachexia is a multifactorial disease that causes continuous skeletal muscle wasting. Thereby, it seems to be a key determinant of cancer‐related death. Although anamorelin, a ghrelin receptor agonist, has been approved in Japan for the treatment of cachexia, few medical treatments for cancer cachexia are currently available. Myostatin (MSTN)...
Alternative Titles
Full title
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9530881
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9530881
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15491
